Semaglo 0.25 mg/0.188 ml (SC Injection)

0.25 mg pre-filled syringe: ৳ 350.00

Medicine Details

Category Details
Generic Semaglutide
Company Ziska pharmaceuticals ltd
Also available as
Semaglo 3 mg tablet Semaglo 7 mg tablet Semaglo 05 mg injection Semaglo ob 025 mg injection Semaglo ob 05 mg injection Semaglo ob 1 mg injection Semaglo ob 17 mg injection Semaglo ob 24 mg injection

Indications

  • Adjunct to diet and exercise for glycemic control in adults with type 2 diabetes mellitus
  • Reduction of risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease
  • Adjunct to reduced calorie diet and increased physical activity for chronic weight management in adult patients with obesity or overweight

Pharmacology

  • GLP-1 analogue with 94% sequence similarity to human GLP-1
  • Stimulates insulin secretion and lowers glucagon secretion in a glucose-dependent manner
  • Reduces body weight and body fat mass by reducing appetite

Dosage & Administration

  • Tablet to be taken at least 30 minutes before the first food, beverage, or other oral medications of the day with no more than 4 ounces (118 ml) of plain water only
  • Starter Dose: 3 mg once daily for 30 days
  • Maintenance Dose: 7 mg once daily after 30 days on 3 mg dose
  • For Additional Glycemic Control: Dose can be increased to 14 mg once daily if needed
  • Injection starting dose: 0.25 mg, then increased to 0.5 mg and finally to 1 mg once weekly for improved glycemic control
  • Site of injection: abdomen, thigh, or upper arm
  • Transition guidelines for switching between injection and tablet for different doses and frequencies

Interaction

  • Delays gastric emptying and can impact the rate of absorption of concomitantly administered oral medicinal products
  • Caution advised when used with oral medicinal products requiring rapid gastrointestinal absorption

Contraindications

  • Hypersensitivity to the active substance or to any of the excipients

Side Effects

  • Potential occurrence of hypoglycemia when used with insulin or sulfonylurea
  • Frequent adverse reactions: gastrointestinal disorder, nausea, diarrhea, vomiting, abdominal pain, constipation
  • Mild or moderate reactions of short duration
  • Other possible reactions: allergic reaction, injection site reaction, lipodystropy, pruritus, rash

Pregnancy & Lactation

  • Not to be used during pregnancy
  • Discontinued at least 2 months before planned pregnancy
  • Not to be used during breastfeeding due to potential risk to the breast-fed child

Precautions & Warnings

  • Not to be used in type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis
  • Prompt discontinuation if pancreatitis is suspected, and should not be restarted if confirmed
  • Monitoring recommended for patients with diabetic retinopathy

Use in Special Populations

  • Safety and efficacy in children and adolescents below 18 years not established
  • No dose adjustment based on age or renal impairment
  • Not recommended for use in patients with end-stage renal disease
  • Caution advised when treating patients with hepatic impairment

Overdose Effects

  • Reported overdose of up to 4 mg in a single dose and up to 4 mg in a week
  • Most commonly reported adverse reaction: nausea
  • No specific antidote for overdose
  • Supportive treatment to be initiated according to patient's clinical signs and symptoms
  • Guidelines for dose adjustment and missed dose administration

Therapeutic Class

  • GLP-1 receptor agonists

Storage Conditions

  • Store at 2°C to 8°C in a refrigerator
  • Do not freeze
  • Keep out of reach of children

Related Brands